Holly, Jeff, 1998. Insulin-like growth factor-1 and new opportunities for cancer prevention. Lancet, 351, 9113, 9 May, 1373–1375.

Chan, J.M., Stampfer, M.J., Giovannucci, E. and others, 1998. Plasma insulin-like growth factor-I and prostate cancer risk; a prospective study. Science, 279, 563–566; Harman, S.M., Metter, E.J., Blackmail, M.R., Landis, P.K. and Carter, H.B., 2000. Serum levels of insulin-type growth factor 1 (IGF-I), IGF II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J. Clin. Endocrinol Metab., 85, 4258–4265; Stattin, P. and nine others, 2000. Plasma insulin-like growth factor-I insulin-like growth-binding proteins, and prostate cancer risk: a prospective study. J. Natl. Cancer Inst., 92, 1910–1917; Chokkalingam, A.P, and 12 others, 2001. Insulinlike growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev., 10, 421–427; Chan, J.M., Stampfer, M.J., Ma, J. and others, 2002. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J. Natl Cancer Inst, 94, 1099–1106; Mantzoros, C.S., Tzonou, A., Signorello, L.B. and others, 1997. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. British Journal of Cancer, 76, 1115–1118; Wolk, A., Mantzoros, C.S., Andersson, S.O. and others, 1998. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl Cancer Inst, 90, 911–915; Holly, J.M.P., Gunnell, D.J. and Davey Smith., G, 1999. Growth hormone, IGF-1 and cancer. Less intervention. Less intervention to avoid cancer? More intervention to prevent cancer. J. Endocrinol, 162, 321–330.